trial

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCTId NCT00794963
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 8 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
8 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2008-11
Primary completion
2010-05
Eligibility
ALL · 19 Years · 79 Years

Interventions & indications

Drugs
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartanAs selected by community physician

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
8
Phase
NA
Primary Completion Date
2010-05
Status
TERMINATED
relationships
The graph out of here
drug
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan
drug
As selected by community physician
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
indication
Metabolic Syndrome
indication
Metabolic Syndrome
indication